메뉴 건너뛰기




Volumn 16, Issue 10, 2006, Pages 1405-1423

Latest advances in cannabinoid receptor antagonists and inverse agonists

Author keywords

Cannabinoid; CB1 antagonists; CB1 inverse agonist; CB2 antagonists; Inverse agonists; JTE 907; Sch225336; SLV319; SR141716; SR147778

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 CHLORO N [[3 (4 CHLOROPHENYL) 4 PHENYL 2 PYRAZOLIN 1 YL](METHYLAMINO)METHYLENE]BENZENESULFONAMIDE; 5 (4 CHLOROPHENYL) 4 (2,4 DICHLOROPHENYL) N (PIPERIDIN 1 YL)THIAZOLECARBOXAMIDE; AMIDE; AZETIDINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; ESTERASE INHIBITOR; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; LIPSTATIN; N PIPERIDINYL 7 BROMO 1 (2,4 DICHLOROPHENYL) 4,5 DIHYDRO 1H THIENO [2,3 G]INDAZOL 3 CARBOXAMIDE; OXAZOLE DERIVATIVE; PYRAZINE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; RIMONABANT; SIBUTRAMINE; SULFONAMIDE; TETRAHYDROLIPSTATIN; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE;

EID: 33750321710     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.10.1405     Document Type: Review
Times cited : (36)

References (53)
  • 1
    • 23444432920 scopus 로고    scopus 로고
    • The endocannabinoid system: Drug targets, lead compounds, and potential therapeutic applications
    • LAMBERT DM, FOWLER CJ: The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J. Med Chem. (2005) 48:5059-5087.
    • (2005) J. Med Chem. , vol.48 , pp. 5059-5087
    • Lambert, D.M.1    Fowler, C.J.2
  • 2
    • 18444376760 scopus 로고    scopus 로고
    • International union of pharmacology. XXVII. Classification of cannabinoid receptors
    • HOWLETT AC, BARTH F, BONNER TI et al.: International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. (2002) 54:161-202.
    • (2002) Pharmacol. Rev. , vol.54 , pp. 161-202
    • Howlett, A.C.1    Barth, F.2    Bonner, T.I.3
  • 3
    • 0037177601 scopus 로고    scopus 로고
    • Endocannabinoid signaling in the brain
    • WILSON RI, NICOLL RA: Endocannabinoid signaling in the brain. Science (2002) 296:678-682.
    • (2002) Science , vol.29 , pp. 678-682
    • Wilson, R.I.1    Nicoll, R.A.2
  • 4
    • 33144480327 scopus 로고    scopus 로고
    • Cannabinoid receptors as therapeutic targets
    • MACKIE K: Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. (2006) 46:101-122.
    • (2006) Annu. Rev. Pharmacol. Toxicol. , vol.46 , pp. 101-122
    • Mackie, K.1
  • 5
    • 27844463517 scopus 로고    scopus 로고
    • Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
    • DESPRES JP, GOLAY A, SJOESTROEM L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Engl. J. Med. (2005) 353:2121-2134.
    • (2005) New Engl. J. Med. , vol.353 , pp. 2121-2134
    • Despres, J.P.1    Golay, A.2    Sjoestroem, L.3
  • 6
    • 17144382751 scopus 로고    scopus 로고
    • Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
    • VAN GAAL LF, RISSANEN AM, SCHEEN AJ, ZIEGLER O, ROSSNER S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365:1389-1397.
    • (2005) Lancet , vol.1365 , pp. 1389-1397
    • Van Gaal, L.F.1    Rissanen, A.M.2    Scheen, A.J.3    Ziegler, O.4    Rossner, S.5
  • 7
    • 32644441249 scopus 로고    scopus 로고
    • Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-north america: A randomized controlled trial
    • RIO-NORTH AMERICAN STUDY GROUP:
    • PI-SUNYER FX, ARONNE LJ, HESHMATI HM, DEVIN J, ROSENSTOCK J; RIO-NORTH AMERICAN STUDY GROUP: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-north america: a randomized controlled trial. J. Am. Med. Assoc. (2006) 295:761-775.
    • (2006) J. Am. Med. Assoc. , vol.295 , pp. 761-775
    • Pi-sunyer, F.X.1    Aronne, L.J.2    Heshmati, H.M.3    Devin, J.4    Rosenstock, J.5
  • 8
    • 33646481040 scopus 로고    scopus 로고
    • Rimonabant: A cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors
    • GELFAND EV, CANNON CP: Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J. Am. Coll. Cardiol. (2006) 47:1919-1926.
    • (2006) J. Am. Coll. Cardiol. , vol.47 , pp. 1919-1926
    • Gelfand, E.V.1    Cannon, C.P.2
  • 9
    • 2942556913 scopus 로고    scopus 로고
    • Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure
    • CLELAND JG, GHOSH J, FREEMANTLE N et al.: Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur. J. Heart Failure (2004) 6:501-508.
    • (2004) Eur. J. Heart Failure , vol.6 , pp. 501-508
    • Cleland, J.G.1    Ghosh, J.2    Freemantle, N.3
  • 10
    • 33745003240 scopus 로고    scopus 로고
    • 1 cannabinoid receptor antagonism: A new strategy for the treatment of 1iver fibrosis
    • 1 cannabinoid receptor antagonism: a new strategy for the treatment of 1iver fibrosis. Nat. Med. (2006) 12:671-676.
    • (2006) Nat. Med. , vol.12 , pp. 671-676
    • Teixeira-clerc, F.1    Julien, B.2    Grenard, P.3
  • 11
    • 0029034879 scopus 로고
    • Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist
    • RINALDI-CARMONA M, BARTH F, HEAULME M et al.: Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. (1995) 56:1941-1947.
    • (1995) Life Sci. , vol.56 , pp. 1941-1947
    • Rinaldi-carmona, M.1    Barth, F.2    Heaulme, M.3
  • 12
    • 19444368081 scopus 로고    scopus 로고
    • 1 cannabinoid receptor antagonists. Drug Discov
    • 1 cannabinoid receptor antagonists. Drug Discov. Today (2005) 10:693-702.
    • (2005) Today , vol.10 , pp. 693-702
    • Lange, J.H.1    Kruse, C.G.2
  • 13
    • 0032787760 scopus 로고    scopus 로고
    • The development of cannabinoid antagonists
    • BARTH F, RINALDI-CARMONA M: The development of cannabinoid antagonists. Cur. Med. Chem. (1999) 6:745-755.
    • (1999) Cur. Med. Chem. , vol.6 , pp. 745-755
    • Barth, F.1    Rinaldi-Carmona, M.2
  • 14
    • 0033815067 scopus 로고    scopus 로고
    • Recent advances in cannabinoid receptor agonists and antagonists
    • GOYA P, JAGEROVIC N: Recent advances in cannabinoid receptor agonists and antagonists. Expert Opin. Ther. Patents (2000) 10:1529-1538.
    • (2000) Expert Opin. Ther. Patents , vol.10 , pp. 1529-1538
    • Goya, P.1    Jagerovic, N.2
  • 15
    • 0036799598 scopus 로고    scopus 로고
    • Recent advances in the cannabinoids
    • ADAM J, COWLEY P: Recent advances in the cannabinoids. Expert Opin. Ther. Patents (2002) 12:1475-1489.
    • (2002) Expert Opin. Ther. Patents , vol.12 , pp. 1475-1489
    • Adam, J.1    Cowley, P.2
  • 17
    • 5744223570 scopus 로고    scopus 로고
    • Recent advances in the cannabinoids
    • HERTZOG DL: Recent advances in the cannabinoids. Expert Opin. Ther. Patents (2004) 14:1435-1452.
    • (2004) Expert Opin. Ther. Patents , vol.14 , pp. 1435-1452
    • Hertzog, D.L.1
  • 18
    • 21044458324 scopus 로고    scopus 로고
    • Current knowledge on the antagonists and inverse agonists of cannabinoid receptors
    • MUCCIOLI GG, LAMBERT DM: Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Cur. Med. Chem. (2005) 12:1361-1394.
    • (2005) Cur. Med. Chem. , vol.12 , pp. 1361-1394
    • Muccioli, G.G.1    Lambert, D.M.2
  • 24
    • 33244484802 scopus 로고    scopus 로고
    • 1 antagonist SR141716: Synthesis and pharmacological evaluation of 1,2,4-triazole-3-carboxamides
    • 1 antagonist SR141716: synthesis and pharmacological evaluation of 1,2,4-triazole-3-carboxamides. Eur. J. Med. Chem. (2006) 41:114-120.
    • (2006) Eur. J. Med. Chem. , vol.41 , pp. 114-120
    • Jagerovic, N.1    Hernandez-folgado, L.2    Alkorta, I.3
  • 27
    • 16244420759 scopus 로고    scopus 로고
    • Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo(g]-indazole-based ligands for cannabinoid receptors
    • MURINEDDU G, RUIU S, MUSSINU JM et al.: Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo(g]-indazole-based ligands for cannabinoid receptors. Bioorg. Med. Chem. (2005) 13:3309-3320.
    • (2005) Bioorg. Med. Chem. , vol.13 , pp. 3309-3320
    • Murineddu, G.1    Ruiu, S.2    Mussinu, J.M.3
  • 28
    • 28544446066 scopus 로고    scopus 로고
    • Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2′,4′-dichloro phenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydr obenzo[6,7]cyclohepta[1,2-c]pyrazole-3-car boxamide
    • MURINEDDU G, RUIU S, LORIGA G et al.: Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2′,4′-dichloro phenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydr obenzo[6,7]cyclohepta[1,2-c]pyrazole-3-car boxamide. J. Med. Chem. (2005) 48:7351-7362.
    • (2005) J. Med. Chem. , vol.48 , pp. 7351-7362
    • Murineddu, G.1    Ruiu, S.2    Loriga, G.3
  • 30
    • 0041321275 scopus 로고    scopus 로고
    • Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α
    • FU J, GAETANI S, OVEISI F et al.: Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature (2003) 425:90-93.
    • (2003) Nature , vol.425 , pp. 90-93
    • Fu, J.1    Gaetani, S.2    Oveisi, F.3
  • 31
    • 3142583174 scopus 로고    scopus 로고
    • Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α)
    • GUZMAN M, LO VERME J, FU F, OVEISI F, BLAZQUEZ C, PIOMELLI D: Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α). J. Biol. Chem. (2004) 279:27849-27854.
    • (2004) J. Biol. Chem. , vol.279 , pp. 27849-27854
    • Guzman, M.1    Lo Verme, J.2    Fu, F.3    Oveisi, F.4    Blazquez, C.5    Piomelli, D.6
  • 32
    • 0042190566 scopus 로고    scopus 로고
    • Melanin-concentrating hormone is a critical mediator of the leptin-deficient phenotype
    • SEGAL-LIEBERMAN G, BRADLEY RL, KOKKOTOU E et al.: Melanin-concentrating hormone is a critical mediator of the leptin-deficient phenotype. Proc. Natl. Acad. Sci. USA (2003) 100:10085-10090.
    • (2003) Proc Natl. Acad. Sci. USA , vol.100 , pp. 10085-10090
    • Segal-lieberman, G.1    Bradley, R.L.2    Kokkotou, E.3
  • 33
    • 0035142565 scopus 로고    scopus 로고
    • Synergistic effects of opioid and cannabinoid antagonists on food intake
    • (Berlin, Germany)
    • KIRKHAM TC, WILLIAMS CM: Synergistic effects of opioid and cannabinoid antagonists on food intake. (Berlin, Germany) Psychopharmacology (2001) 153:267-270.
    • (2001) Psychopharmacology , vol.153 , pp. 267-270
    • Kirkham, T.C.1    Williams, C.M.2
  • 35
    • 22544439953 scopus 로고    scopus 로고
    • Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors
    • IDRIS AI, VAN'T HOF RJ, GREIG IR et al.: Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat. Med. (2005) 11:774-779
    • (2005) Nat. Med. , vol.11 , pp. 774-779
    • Idris, A.I.1    Van't Hof, R.J.2    Greig, I.R.3
  • 41
    • 24344509882 scopus 로고    scopus 로고
    • Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies
    • SHANKAR BB, LAVEY BJ, ZHOU G et al.: Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies. Bioorg. Med. Chem. Letters (2005) 15:4417-4420.
    • (2005) Bioorg. Med. Chem. Letters , vol.15 , pp. 4417-4420
    • Shankar, B.B.1    Lavey, B.J.2    Zhou, G.3
  • 42
    • 33748780355 scopus 로고    scopus 로고
    • 2) expression and pharmacology using a novel radioligand
    • 35S]SCH225336 ahead of print June 206 DOI 10.1074 /jbc.M602364200
    • 35S]SCH225336. J. Biol. Chem. (2006) ahead of print June 206 DOI 10.1074/jbc.M602364200.
    • (2006) J. Biol. Chem.
    • Gonsiorek, W.1    Hesk, D.2    Kinsley, D.3
  • 43
    • 31144468211 scopus 로고    scopus 로고
    • A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo
    • LUNN CA, FINE JS, ROJAS-TRIANA A et al.: A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J. Pharmacol. Exp. Ther. (2006) 316:780-788.
    • (2006) J. Pharmacol. Exp. Ther. , vol.316 , pp. 780-788
    • Lunn, C.A.1    Fine, J.S.2    Rojas-Triana, A.3
  • 45
    • 0028129936 scopus 로고
    • SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
    • RINALDI-CARMONA M, BARTH F, HEAULME M et al.: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350:240-244.
    • (1994) FEBS Lett. , vol.350 , pp. 240-244
    • Rinaldi-carmona, M.1    Barth, F.2    Heaulme, M.3
  • 46
    • 85047690626 scopus 로고    scopus 로고
    • The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis
    • COTA D, MARSICANO G, TSCHOP M et al.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. (2003) 112:423-431.
    • (2003) J. Clin. Invest. , vol.112 , pp. 423-431
    • Cota, D.1    Marsicano, G.2    Tschop, M.3
  • 47
    • 1842866963 scopus 로고    scopus 로고
    • 1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity
    • 1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. (2004) 28:640-648.
    • (2004) Int. J. Obes. , vol.28 , pp. 640-648
    • Ravinet Trillou, C.1    Delgorge, C.2    Menet, C.3    Arnone, M.4    Soubrie, P.5
  • 49
    • 0037374766 scopus 로고    scopus 로고
    • 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells
    • 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. (2003) 63:908-914.
    • (2003) Mol. Pharmacol. , vol.63 , pp. 908-914
    • Bensaid, M.1    Gary-bobo, M.2    Esclangon, A.3
  • 50
    • 12744260206 scopus 로고    scopus 로고
    • The anti-obesity effect of rimonabant is associated with an improved serum lipid profile
    • POIRIER B, BIDOUARD JP, CADROUVELE C et al.: The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes. Metab. (2005) 7:65-72.
    • (2005) Diabetes Obes. Metab. , vol.7 , pp. 65-72
    • Poirier, B.1    Bidouard, J.P.2    Cadrouvele, C.3
  • 51
    • 12744258029 scopus 로고    scopus 로고
    • 1 receptors
    • 1 receptors. Life Sci. (2005) 76:1307-1324.
    • (2005) Life Sci. , vol.76 , pp. 1307-1324
    • Pertwee, R.G.1
  • 52
    • 29844447996 scopus 로고    scopus 로고
    • Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'
    • GARDNER A, MALLET PE: Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. Eur. J. Pharmacol. (2006) 530:103-106.
    • (2006) Eur. J. Pharmacol. , vol.530 , pp. 103-106
    • Gardner, A.1    Mallet, P.E.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.